General
Preferred name
FLUOROURACIL
Synonyms
5-fluorouracil ()
5-FU ()
Fluorouracil (Adrucil) ()
NSC 19893,5-Fluorouracil, 5-FU ()
Fluorouracil (5-Fluorouracil, 5-FU) ()
5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione ()
FluorouracilEfudex5-FU5-FluorouracilAdrucil5-Fluoro-2,4-pyrimidinedione5-Fluoropyrimidine-2,4-dione5-Fluoro-2,4(1H,3H)-pyrimidinedioneUracil, 5-fluoro-Effluderm (free base) ()
Actikerall ()
5-Fluorouracil ()
Fluorouracil component of folfox ()
Fluoroplex ()
RO 2-9757 ()
Queroplex ()
Adrucil ()
Phthoruracil ()
Accusite ()
RO-2-9757 ()
Carac ()
Fluorouricil ()
5 FU ()
5-fluoruracil ()
Efudix ()
NSC-19893 ()
Fluorouracilo ()
Fluracil ()
Tolak ()
Ro-29757 ()
Efudex ()
5.F.U. ()
Fluorouracilum ()
Fluoro-Uracil Roche ()
5-Fluorouracil-13C,15N2 ()
P&D ID
PD002327
CAS
51-21-8
1004-03-1
4921-97-5
1189423-58-2
Tags
available
drug
Approved by
PMDA
FDA
First approval
1962
Drug indication
Tumour
Colorectal cancer
colorectal adenocarcinoma
Solid tumour/cancer
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour.; The remaining percentage of the administered dose is metabolized, primarily in the liver.
DESCRIPTION Fluoroacil is the active metabolite of the prodrugs and . (GtoPdb)
DESCRIPTION 5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibits HIV[3].
PRICE 29
DESCRIPTION 5-Fluorouracil (5-FU) is a uracil analog and inhibitor of DNA synthesis, exhibiting antitumor activity by affecting pyrimidine synthesis through thymidylate synthase inhibition; it induces apoptosis and autophagy.
DESCRIPTION pyrimidine analog; inhibitor of thymidylate synthase (Informer Set)
DESCRIPTION Selective, reversible FAAH inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Thymidylate synthetase inhibitor; leads to accumulation of cells in S phase (LOPAC library)
DESCRIPTION Fluorouracil is a pyrimidine analog that is an antineoplastic antimetabolite. It is used to treat basal cell carcinomas, and as an injection in palliative cancer treatment. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. (Enamine Bioactive Compounds)
DESCRIPTION Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay; PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 918 ]; PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) (TargetMol Bioactive Compound Library)
Cell lines
216
Organisms
6
Compound Sets
40
AdooQ Bioactive Compound Library
A10042
Cayman Chemical Bioactives
14416
26683
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL185
ChEMBL Drugs
CHEMBL185
Concise Guide to Pharmacology 2017/18
4789
Concise Guide to Pharmacology 2019/20
4789
Concise Guide to Pharmacology 2021/22
4789
Concise Guide to Pharmacology 2023/24
4789
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00544
DrugBank Approved Drugs
DB00544
DrugCentral
26
DrugCentral Approved Drugs
26
DrugMAP
DMUM7HZ
DrugMAP Approved Drugs
DMUM7HZ
DrugMatrix
Enamine Bioactive Compounds
EBC-00529
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101699
Guide to Pharmacology
4789
Informer Set
25344
LINCS compound set
10238-101
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL185
Mcule NIBR MoA Box Subset
MCULE-6338086431
MedChem Express Bioactive Compound Library
HY-90006
NCATS Inxight Approved Drugs
U3P01618RT
NIH Approved Oncology Drugs
82653
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Adrucil(Fluorouracil)
TargetMol Bioactive Compound Library
R052-0877
The Spectrum Collection
Tocris Bioactive Compound Library
3257
Welcome Trust Cancer Drugs
179
External IDs
63
Properties
(calculated by RDKit )
Molecular Weight
130.02
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
0
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.8
TPSA
65.72
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
TYMS
DNA antimetabolite
Thymidylate Synthase
DNA
RNA
DPYD, TYMS
Apoptosis
Endogenous Metabolite
HIV
Nucleoside antimetabolite/analog
Apoptosis related,DNA/RNA Synthesis,HIV,Nucleoside Analog/Antimetabolite,Thymidylate Synthase
Compound status
FDA
Pathway
DNA replication
Anti-infection
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Selectivity
Thymidylate synthetase
MOA
Thymidylate synthase inhibitor
DNA/RNA Synthesis
Inhibitor
thymidylate synthase
Primary Target
Thymidylate Synthetase
Member status
member
Indication
colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma
Therapeutic Class
Immunosuppressive Agents
Source data